Do you - also - think the world is flat and the human was not on the Moon? Who is Euro-centric BP? All Co. - especially pharmas - are WORLD centric ...

So 100% of the existing management - at any co. - failed, since it is a standardWorst thing to do ...

h-

Meanwhile "future" includes tomorrow ... it will not be a straight up.

I had shares
- between 2013-2020 ... sold @$6.49
- April - May 2022 ... sold @$1.89
- If I feel the time is right I will have shares .... sold before 10-Q2 release

Do you familiar with 'opportunity cost' definition .... ?
What would you like doing differently (management)?

Best,
G

ps.: I am in CFRX right now ... we will see

r-

I acknowledge it earlier (in a post) ...

Both were about compensation (easier to get a "no" vote) furthermore 5. was w/o "any" meaning ... it was a non-binding advisory vote

Best,
G

O-

I think sentiment expressed on this board does not necessarily reflects the current sentiment of all shareholders ... at least the votes suggests this. I mean: Meanwhile Sarissa gave a notice in advance about "Abstain" less than the 50% of outstanding voted (188 / 400) and - by thigh margin, but - "For" was more than "Against + Abstain".

Is it the best management ever? Definitely not, but they are OK. Looks like they are doing "everything" for long term success.

US:
- restructuring the operation (inc. cut sales force, cur and reallocate marketing expense between "channels")
- secure app. 50% of the market (the script# - at least - was stabilized in this segment and a good basis for growth ... this could "force" one or more generic to leave the market on mid- / long-term ... please note: Teva or Apotex did not enter)

EU:
- they submitted the application in all key markets ... secured UK (& Sweden) and - at least - Germany and France will come during the next few months
- the process takes time ... they are not slow. IF we "accept" that they are slow, it is because they are not give up long-term opportunity (higher price) for "speed" / short-term gain (earlier agreement)
- they secured (and more likely will in other countries) a very good price and reimbursement (e.g. highest category in France). IIRC drug prices in the EU are lower (usually) than in the US but Vascepa secured higher price than the V's price before generic
- ongoing discussion for non-GIA EU countries / regions

Rest of the world:
- submitted application in several market
- ongoing discussion for several countries / regions

Best,
G

l-

??? How / what do you mean?

If the outstanding shares is 400M (rounded number in this case): how many holders - acc. to you exist?

a.) Is it 400M (inc. - e.g. - Sarissa as 24M holders)?
or
b.) Is it different number? (Please explain)

Best,
G

l-

I am correct and Denner' release is wrong? How is it possible?

Best,
G

O-

W/o checking the law I agree: the logic dictate this ... I just quoted Denner ...

Best,
G

Maybe I am misunderstanding something ... and I did not check (the exact law) because it was written by Sarissa / Denner ...

Good luck ... it is at least (app.) 200M votes.

Best,
G

ps.: IF he means - but could not express himself ... - that majority of vote cast (outstanding shares presented / represented on the special meeting) the chance is better but based on the recent meeting is not guaranteed.

z-

The point? You did not provide anything to support this. If their history suggests anything it suggests the opposite ... Ekman hired PWO???

Meanwhile Ekman was the member of the Nominating and Corporate Governance Committee and the Chairman / member of the Board ... he is one member only among others.
New MoB are recommended by the Nominating and Corporate Governance Committee and the Board voted ... so it was Elkman's hire. Retired (as Chairman)? ... Not likely.

Per Wold-Olsen joined in January, Erin S. Enright and Alfonso Zulueta joined in May ... 3 members of the 8 was new ... so the Board make a new election / voting about the Chairman position in May ... and the 8 members - by voting - elected PWO. Ekman has a special "count" - as a Chairman if it is necessary - voting result is 50/50 - to decide something

It was not a one and only change / reorganization in May:
- the Audit Committee: new Chairman Enright (instead of van Heek)
- Remuneration Committee: new Chairman Wold-Olsen (instead of Stack)

Best,
G

z-

Where did you see it? Top of the above ... How? Merck bought Nova Cardia in 2007 meanwhile LE was EVP, President of Research & Development @ Elan since 2001 January till joined to Sofinova in 2007.

Best,
G

J-

Thx, my fee is
- pps > 3 USD:0,2% + 5.000 HUF (app. 12-13 USD)
- pps < 3 USD: 0,0045 USD / pcs + 5.000 HUF (app. 12-13 USD)

But ... Are you charged by GDR administration fee? Not by DBS Vickers. I was not charged by my broker, I was charged by the US registrator of the GDR.

Best,
G

K-

If a $25 BO will happen I would buy the Harley for you ...

Best,
G

z-

What about are you talking? The CEO is Karim Mikhail. PWO is / was one of the members of the Board only ... appointed on January 10, 2022 ... became the Chairman in May 2022. Furthermore, why do you think he became a member due to Ekman ... unless I missed something they were not on the same board of any co. ever.

Best,
G

l-

I do not think it belongs to my citizenship ... it is due to because the type of the "share". GDR is a certificate issued that represents shares in a foreign stock on two or more global markets.

I was not charged previously (2013-2020) just for my recent holding: $295 for May and $105 for June (sold on June 8).

Best,
G

ps.: I am curious to know I was the "one and only" or somebody else was charged by the same type of fee.

T-

I know ... (maybe) you have to send it to l-.

Best,
G

l-

??? Do you see HLS as a BP ...?

Pfizer is responsible education about Vascepa with primary care physician only ... everything else - especially reimbursement - done by HLS.

btw: what do you mean as "so successful with vascepa"?

Best,
G

K-

It is not that, but ... Best,
G

K-

Best,
G

l-

I do not know why it was charged now. I was charged between Aug 28, 2013 - April 17, 2020, meanwhile I owned AMRN. I continuously checking tickers mentioned in newsletter, post, at other ticker, etc. ... make a quick look, overview ... if it pass it bookmark as "pick" ... make a more deep DD ... if it pass I follow ... if think time and price is right: buy I saw it as get ANCHOR ... but it is history. I keep it because I thought R-IT will be a success ... it was. Did not sell as I expected a BO ... but did not anymore after the patent case (or anytime in the future), so I sold in April, 2020 @ 6.49.
......
Bought @2.74 ... and significantly average down after the 10-Q1 ... sold @1.89 ... invest in other ticker (CFRX). I plan to reinvest in AMRN - after I sold CFRX - since I think it is worth more than $1.4x ... I do not say it is the bottom or it will be $2.xx next week ... but the current pps effect the timing of my entry only. I still expect volatility - we could see 1.2y one day and 1.8x on the other and 1.5x next day - but definitely did not expect a BO in the near-, short- mefium-term ...

Best,
G

n-

So, it was not yours. Numbers are based on record date.

Best,
G

m-

If "everything" (but at least one thing) will go as expected maybe / more likely I will be "in" again in the near future ...but till T-1 day only (T day: Q2 release).

Best,
G

l-

I did not check / follow-up, just paid.

GDR fees are custody fees, sometimes referred to as Depositary Services Fees, to compensate the depositary banks for inventorying the non-U.S. shares and performing registration, compliance, dividend payment, communication, and record keeping services.

Best,
G

s-

April 4, 2022: "We currently anticipate results from the interim futility analysis in the first half of 2022."

May 16, 2022: "we have eclipsed the enrollment threshold, meaning over 60% of the methicillin-resistant Staph aureus (MRSA) patients, needed for the interim futility analysis of our Phase 3 DISRUPT study to be conducted and we currently have about two-thirds of the entire study population enrolled as well" ... "We expect this to occur during the first week of July"

Analysis is ongoing since (as the latest) May 30 (May 16 + 14 days) ... but more likely started earlier, since app. 66% was enrolled by May 16.

Anytime ... and not later than July 15. Does Super Tuesday exist in July?

Best,
G

l-

Yes, I bought on Apr 29 and - the majority - on May 4 ... sold on Jun 8 @ $1.8904 (Unfortunately, I was back in home too early and cancelled the $1.99 sell order which was submitted while I was away ... )

Wednesday, June 08, 2022 3:40:41 PM
btw: I was charged by $295 as GDR registration fee

Best,
G

l-

???. Of course not, but all outstanding could. The shorts ... the naked shorts could "influence" the vote as could generate more eligible vote - but not by shorts - than the outstanding shares. Yes, anyone who owned those shares at the time of last proxy vote Because the broker did not get any instruction how to vote with these shares (94,134,724). Top of it other 118,151,359 shares* did not vote ... 212,286,083 did not vote as "For" or "Against" or "Abstentions" ... 53% of the outstanding.
* Dunno where this share are ... maybe these are owned by overseas Nope ... never called me*, but I ignore a lot of relentless and that human does not exist who could get my vote if it is not my intention.
(*I was not could by any proxy solicitor ever, inc. the current AMRN's proxy, meanwhile I own shares.)
Best,
g

Few thoughts about vote result (2022 vs 2021, in millions):

(I) The outstanding shares was a little bit higher: 397 vs 395 (+2) … I think / assume the increase was 100% insiders. (I assume a “votes for” by these shares.)

(II) The voting shares* increased to 185 (from 143; + 42 / +29% … +39 / +28% exc. insiders above) … however it was the 47% of the outstanding shares (397).

*Please note: “Broker Non- Votes” was entitled to vote on accounting firm only, as a “routine” proposal … without this agenda point this type of vote does not count as present. Abstentions and broker non-votes counted for determining the presence or absence of a quorum, but will not be counted for determining the number of votes cast on a given proposal.

(III) We “know”:
a) Sarrissa has: 24
b) Baker B has: 21
c) Votes increased by 42 (39 exc. insiders)
d) “Broker votes” increased by 20 (I think fair to assume these are all individuals)
e) Non-individuals, non-insiders increased by 19 (as it is less than what BB has, I assume that BB voted in 2021)

(IV) re-elect Mr. Karim Mikhail (lowest “votes for” among re-election) vs re-elect Mr. Patrick J. O’Sullivan (highest “votes for” among re-election)

For: 93 vs 109: -16 … 91 vs 109 (exc. the +2 belongs to insiders, see I.): -18
Against: 37 vs 29: +8
Abstentions: 55 vs 5: +50 (w/o Sarissa: 31 vs 5: +26)
Against + Abstentions: 92 vs 34: +58 (w/o Sarissa: 68 vs 34: +34)

Who could be behind the change? (Against + Abstentions; w/o Sarissa: 68 vs 34: +34)
(i) +20: “new” individuals (Fair to assume they did not vote “For” and as it less than Sarissa’s 24, fair to assume that Sarissa’s current shares voted in 2021)
(ii) +14: individuals and institutions who voted in 2021 (as it and the decrease of "For" are less than BB’s shares, fair to assume that – at least part, but more likely full – they voted “For”.)

For vs Against + Abstentions: 93 vs 92 … approved
(Just for the record “best” re-election: 95 vs 89)

Altogether, I am not sure Denner is “comfortable” enough with the outcome to initiate a special meeting (especially if the pps will be higher …).
(i) 39 / 28% increase in total votes (exc. insiders 2) … 212 million did not vote.
(ii) all re-election was approved (with a tight margin, but was approved counting “Abstentions” as “Against”) … meanwhile the pps is below $2.

We could see a (one) board membership for him w/o a special meeting ... or (but I am not sure we will know it) he could be an advisor for the Board. ... or everything will be the same.

Best,
G

ps.: vote about Compensation Plan was more favorable “for Denner” but that does not matter
(i) everybody “love” to vote against compensation
(ii) it was a non-binding advisory vote

m- (& rosemountbomber 382130 + 382133)

Meanwhile AgV should not be cheaper than V, usually Ag is cheaper than brand. I think / view as the Co. try to secure as much as possible exclusive deal ... see the reaction by generics to the shrinking market ... if it necessary / helps launch AgV. At least the latter - will continue - but more likely both ("signing" / upfront bonus). (i) discounts/rebates was one effect only (top of lower script#) the whole sale inventory level (WSIL) affected the revenue also. WSs used the Q4 inventory in Q1 (as usual, as in every year) but top of it the WSIL was at the minimum
(ii) The higher discounts/rebates is not a new element, more likely it was introduced in Q2 2021*. It has a big effect for Q1 2022 (vs Q1 2021) but more likely will have a lower effect for Q2 2022 vs Q2 2021 (* Dispensed script was +2% - Q2 vs Q1 2021, but Rebates,Chargebacks and Discounts increased by 17%... and the exclusive deal was 40% by EOY 2021)
(iii) The Q2 2022 Net Revenue depends - mainly - on the WSIL and I expect a higher level than in Q1 ... Net Revenue +20% vs Q1.(My guess: at least $110-115M) The Company expects these actions will reduce operating costs by approximately $100 million over the next 12 months ... app. / avg. $8M per month. Amarin estimates that it will incur approximately $10.0 million in charges and record the charges in the second quarter (make substantially all of the related payments by the end of 2022.) Net effect: $90 million over the next 12 months ... +$10 (or +2) million for Q2. It is top of the $30.0 million marketing cut ... the two (three) together is $120 (100 - 10 + 30) million over the next 12 months ... app. / avg. $10M per month ... could be +/- 0 (or + ) for Q2

Best,
G

K-

Agree Why you did not quote the whole ...? It is not entertaining ... at least not for me. If you are entertained by these type of post ... well in that case ...

Best,
G

K-

It was $180 but it is $167 now ... I used the recent exchange rates ... so let me rephrase:

Sweden: 1.640 SEK ($159 / 152 €) .. .SEK/USD: 0.097
UK*: €144.21 ($174 / 167 €) ... GBP/USD: 1.21

So yes: $160-$170 (now) ... 155-165 € ... actual, reported revenue depends on actual exchange rate, as EU price will be fixed in local currency (EUR, SEK, GBP, HUF, etc.) but will be reported in USD.

* A lot of EU countries are using UK as reference price

Best,
G

m-

"Denner effect":
(i) MDCO has appointed Dr. Alexander Denner to its Board of Directors ... Shares of The Medicines Company were trading higher by around 1 percent mid-Wednesday afternoon. ... February 3, 2016 ($33.62; +0,76)
pps till (ii): app. $29 - 54

(ii) Medicines Co. is restructuring its board, cutting to 7 members from 12. More than half of the smaller slate has ties to activist investor Alex Denner of Sarissa Capital. March 1, 2018 ($33.27; +2,65 ... local peak on 03/13 @ $35.91)
pps till (iii): app. $17 - 40

(iii) last "low" on August 12, 2019: app. $31

(iv) MDCO: $58.65 on November 18, 2019 -> BO effect: $ 83.80 November 25, 2019

So:
a.) It is not a short story and he is before (i) now ... control of the Board is far away
b.) His success (I mean gain control of the Board) will depends on the Co performance (the pps) and I think by EOY23 it will be much higher

Again, it is not about / against Denner, but I do not build expectation, investment based on "these".

Best,
G

m-

IIRC they expect to reach 50+% ... maybe it could go up to 55-60%. As we say: It is better to get fillérs (vents) often than forints (dollars) seldom ... (a bird in the hand is better than two in the bush)

I definitely agree with this strategy:
(i) they stabilized the script# in this segment (meanwhile 15-20% decline in the other)
(ii) still a good 70-75% gross profit
(iii) maybe it could lead to the decision by the generics that they are not interested in gV anymore (I mean the 40-45% of a not too big market - due to early entry - will not be attractive enough for them.)

Best,
G

N-

For me also (increased by 1.300%) and sold @ $1.89.

Best,
G

r-

Nothing special ... and was not about or against Denner.

Unless I missed something he bought the majority (app. 17-18M) of the 24M shares before November 26, 2021 ( 13D ), however he did not request a board seat, just recently, after the drop in the pps (meanwhile the Board was changed).

I am fine with "him" on a Board (he could bring new perspective), however I do not think (like others): (i) he will take the (majority of) the Board (ii) will change everything (especially as the Co is going in the right direction).

I think he see the current situation as a good point to request a seat ... maybe he will get it ... but I will not be surprised if he will not get it and he will not fight.

That's all.

Best,
G

ps.: I could not stand to skip it (it was not behind ma original post, just because your post ) ... Board seat is a perfect position to gain inside information ...

None of the most discussed topics - ongoing studies, STAT article, management, etc. - are important on a real (long-) term. All of these are micro-management ... the worst thing that any company could do ...

They have to - and they are doing it - focus on:
- US exclusivity (45% by 3/21/2021) and optimal operation* method (it is - due the current world - is significantly different than a 1 year ago (generics are a part of it only)
- EU roll-out ... as more likely they will get $160-170 USD price (before mandatory discounts, rebates) in all important countries (France, Germany, Italy, etc.)
- a much as possible licensing / cooperation in non GIA countries / territories

The pps will follow these ...

Best,
G

ps.: Do anybody really think (I know a lot of you hope ...) that Denner will change the world ... ? Do he would like to change the world? Hello!!! He voted "abstain", not "against" ...

ps II. the most silly, laughable posts when it is about other posters ...

N-

I think: V + gV. (exc. gL)

Best,
G

K-

(i) US had $200+ M profit* in 2021 (*contribution margin, defined as U.S. gross profit less U.S. sales and marketing-related expenses)
(ii) $30 million reduction in annual marketing expenses. to maintain positive contribution margin
(iii) the June actions (including a comprehensive cost and organizational restructuring plan to address current shifts within the Company’s U.S. business) will reduce operating costs by approximately $100 million* over the next 12 months and enable Amarin to maintain a positive contribution margin in the U.S (*net $90 million inc. approximately $10.0 million in charges related to the CRP)

Best,
G

m-

I do not know but the Co linked incentives to 50% market share.Best,
G

l- show me where s/he said s/he bought AMRN for 1.20 ... GTC is more likely GTCH than AMRN ...

Best,
G